TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02006238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Farabloc
Description: The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Farabloc
Description: The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nylon Fabric
Description: The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nylon Fabric
Description: The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
Study: NCT05447949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuncts to levobupivacaine in Erector Spinae Plane Block
Description: The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuncts to levobupivacaine in Erector Spinae Plane Block
Description: The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjuncts to levobupivacaine in Erector Spinae Plane Block
Description: The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Study: NCT04382599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with octagon background
Description: The warning message is in white text on a black octagon background

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about
Study: NCT01282424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg tablet administered orally twice daily
Study: NCT00573963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine
Description: 2 injections of 20mL 0.375% ropivacaine - one given on each side.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 2 injections of 20mL plain saline solution - one on each side.
Study: NCT02268981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® compared to CNC
Description: Oxygen Saturation measurement for 12 h with CNC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® compared to CNC
Description: Oxygen Saturation measurement for 12 h with Oxymizer®

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxymizer® compared to CNC
Description: Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
Study: NCT00338195

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Individualized caffeine cessation instructions
Description: Intervention is described in the protocol
Study: NCT04382599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Icon warning
Description: The warning message in in white text on a black background, below an icon that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic warning
Description: The warning message in in white text on a black background, below a graphic that conveys the topic the warning is about
Study: NCT03315325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human kisspeptin-10 (metastin 45-54)
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human kisspeptin-10 (metastin 45-54)
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human kisspeptin-10 (metastin 45-54)
Description: Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
Study: NCT01130805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib in combination with capecitabine and oxaliplatin
Description: Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
Study: NCT05041179

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pruvin R
Description: Combination of N-acetylcysteine an glycine
Study: NCT03586284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Hydrochloride
Description: 21 to 28 days of oral valganciclovir treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir Sodium
Description: 21 to 28 days of topical ganciclovir solution treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 21 to 28 days of placebo pill treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 21 to 28 days of placebo pill treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical placebo
Description: 21 to 28 days of topical placebo treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo
Description: 21 to 28 days of topical placebo treatment
Study: NCT05041179

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pruvin R
Description: Combination of N-acetylcysteine an glycine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pruvin R
Description: Combination of N-acetylcysteine an glycine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isomaltulose
Description: Placebo as comparator to intervention
Study: NCT04032522

Intervention type: OTHER
Intervention: point-of care (PoC) neonatal HIV early infant diagnosis (EID)
Description: clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
Study: NCT03555526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: metronidazole, 500mg, bid, for 7 days (day 8-14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole, 500mg, bid, for 7 days (day 8-14)
Study: NCT04024254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid Tablet
Description: Folic Acid 1 mg by mouth daily
Study: NCT03312036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration and adsorption (CPFA)
Description: Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation
Study: NCT01983566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 high fat
Description: BI 207127 as a single dose after a high fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 with Omeprazole
Description: BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
Study: NCT02830724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: For Phase I, Days -7 and -6:~Dose Level 1: 15 mg/kg/day x 2 days IV Dose Level 2: 15 mg/kg/day x 2 days IV Dose Level 3: 15 mg/kg/day x 2 days IV Dose Level 4: 15 mg/kg/day x 2 days IV Dose Level 5: 30 mg/kg/day x 2 days IV Dose Level 6: 60 mg/kg/day x 2 days IV~For Phase II, Days -7 and -6:~60 mg/kg/day x 2 days IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB
Study: NCT03555526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: levofloxacin 250mg, bid, for 7 days (day 8-14)
Study: NCT01983566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127
Description: BI 207127 as a single dose in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 low fat
Description: BI 207127 as a single dose after a low fat breakfast
Study: NCT02830724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: For Phase I, Days -7 to -5:~Dose Level 1: 25 mg/m(2)/day x 3 days IVPB Dose Level 2: 25 mg/m(2)/day x 3 days IVPB Dose Level 3: 25 mg/m(2)/day x 3 days IVPB Dose Level 4: 25 mg/m(2)/day x 3 days IVPB Dose Level 5: 25 mg/m(2)/day x 5 days IVPB Dose Level 6: 25 mg/m(2)/day x 5 days IVPB~For Phase II, Days -7 to -3:~25 mg/m(2)/day x 5 days IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-hCD70 CAR transduced PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-hCD70 CAR transduced PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-5 days after the last dose of fludarabine).
Study: NCT01319747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS-PVI
Description: A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
Study: NCT03555526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: levofloxacin 250mg, bid, for 7 days (day 8-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER
Description: clarithromycin 500mg, bid, for 7 days (day 8-14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin ER
Description: clarithromycin 500mg, bid, for 7 days (day 8-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 10 days
Study: NCT02236039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
Study: NCT03555526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Nexium (esomeprazole), 40mg, bid, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibismuth trioxide
Description: Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
Study: NCT03032575

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SEARCH010/RV254
Study: NCT04462354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blumgart Anastomosis
Description: Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Blumgart anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatogastric anastomosis.
Description: Patients undergoing cephalic duodenopancreatectomy, reconstructing pancreatic-enteric communication by Pancreatogastric anastomosis.
Study: NCT02902757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study: NCT04495296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day
Study: NCT00364767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A
Description: Alcohol consumption (32 g/day) for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B
Description: Water
Study: NCT02431611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biomarker feedback (phone based smoking cessation counseling)
Description: Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition (phone based smoking cessation counseling)
Description: phone-based behavioral smoking cessation counseling
Study: NCT02302417

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spirometry
Description: Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility

Intervention type: OTHER
Group type: OTHER
Intervention: ACOS clinical questionnaire
Description: The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
Study: NCT03655405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Deprescribing Intervention
Description: The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
Study: NCT04495296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST001
Description: TST001 will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered by specified doses on specified days Oxaliplatin will be administered by specified doses on specified day Drug: Capecitabine Capecitabine will be administered by specified doses on specified day
Study: NCT03555526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dibismuth trioxide
Description: Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
Study: NCT04495296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered by specified doses on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered by specified doses on specified day
Study: NCT03555526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metronidazole
Description: metronidazole, 500mg, tid, for 10 days (day 1-10)
Study: NCT01410747

Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study: NCT04587635

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PHGG
Description: PHGG

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin